安琪酵母拟投5.02亿建生物智造中心

Core Viewpoint - Angel Yeast (600298.SH) is advancing its biotechnology research and industrialization process with a new investment of approximately 502 million yuan in a biomanufacturing center project, reinforcing its strategic goal of becoming a leading global yeast and biotechnology company [1][2]. Group 1: Investment and Projects - The biomanufacturing center project is estimated to cost 502 million yuan, funded by the company's own resources, and is planned to be located next to the company's headquarters, covering an area of about 23 acres, with completion expected in the second half of 2027 [1]. - In addition to the biomanufacturing center, Angel Yeast announced a 230 million yuan investment in a serum-free cell culture medium core technology project, aimed at enhancing product innovation and market transition [2]. Group 2: Market Position and Financial Performance - Angel Yeast is the second-largest yeast company globally, with a total yeast production capacity exceeding 450,000 tons, holding a 55% market share in China and over 20% globally [1]. - The company has maintained stable revenue growth since surpassing 10 billion yuan in revenue in 2021, with projected revenue of 15.197 billion yuan for 2024. In Q1 2025, the company reported total revenue of 3.794 billion yuan, reflecting an 8.95% year-on-year increase, and a net profit of 370 million yuan, up 16.02% year-on-year [2].